Operations

Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

November 9, 2017

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2017, along with a general business update.   “Reconciliation of GAAP […]

AmpliPhi Biosciences to Hold 2017 Third Quarter and Business Update Conference Call on November 14

November 9, 2017

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business update conference call on Tuesday, November 14, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   Live Call:                                […]

Akebia Therapeutics Announces Third Quarter 2017 Financial Results

November 9, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2017.   “Akebia continues to execute on our global Phase 3 program for vadadustat in collaboration with our […]

Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update

November 9, 2017

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2017.   $ZYME Reports Third Quarter 2017 Financial Results and Provides Business Update Tweet this “During the third quarter, we provided an […]

Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results Prepares for Q4 2017 FDA Approval and Q1 2018 Commercial Launch

November 9, 2017

CHARLESTON, S.C.–(BUSINESS WIRE)–Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies, today reported financial and operating results for the third quarter ended September 30, 2017.   “We are continuing our laser focus on preparation for the FDA approval of Macrilen™ by December 30, […]

Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations

November 9, 2017

WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2017. Revenue from continuing operations was $464.2 million, an increase of 9.0% from $425.7 million in the third quarter of 2016. Revenue growth was driven primarily by the Discovery and Safety Assessment and Manufacturing Support segments.   […]

ArQule Reports Third Quarter 2017 Financial Results Conference call scheduled today at 9:00 a.m. ET

November 9, 2017

BURLINGTON, Mass.–(BUSINESS WIRE)–ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2017.   “Based on the preliminary results from the phase 1 NIH-sponsored Proteus syndrome trial, miransertib is the first drug to demonstrate activity and achieve clinical proof of concept in this indication” Tweet this For the quarter ended September […]

Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update

November 9, 2017

LEXINGTON, Mass.–(BUSINESS WIRE)–Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017.   “This is an exciting time for our deuterium-based chemistry as we continue to demonstrate our technology’s ability to meaningfully improve the clinical properties of existing medicines. The CTP-656 program and subsequent asset purchase agreement with Vertex Pharmaceuticals […]

Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update

November 9, 2017

CORAL GABLES, Fla., Nov. 08, 2017 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2017 and provided a corporate update. “We have made significant […]

Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering

November 9, 2017

MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly […]

Sarepta Therapeutics Prices $475 Million of Convertible Senior Notes Due 2024

November 9, 2017

CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the pricing of $475 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024. The notes […]

Apellis Pharmaceuticals Announces Pricing of Initial Public Offering

November 9, 2017

CRESTWOOD, Ky., Nov. 08, 2017 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its initial public offering of 10,714,000 shares of common stock at a public offering price of […]

INC Research/inVentiv Health Reports Third Quarter 2017 Results

November 9, 2017

RALEIGH, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) — INC Research (NASDAQ:INCR), which, following the completion of the merger on August 1, 2017 with inVentiv Health (“the Merger”), we refer to as INC Research/inVentiv Health (“the Company”), the only fully-integrated biopharmaceutical solutions organization combining a CRO and a CCO (Contract Commercial Organization), today reported financial results […]

ContraFect Announces Third Quarter 2017 Financial Results

November 9, 2017

YONKERS, N.Y., Nov. 09, 2017 (GLOBE NEWSWIRE) — ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for the third quarter ended September 30, 2017. This quarter, ContraFect completed a public stock offering raising net proceeds of $37.1 million. […]

Nabriva Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights

November 9, 2017

DUBLIN, Ireland, Nov. 09, 2017 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its financial results for the quarter […]

BioLineRx to Report Third Quarter 2017 Results on November 21, 2017

November 9, 2017

TEL AVIV, Israel, November 9, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the quarter ended September 30, 2017 on Tuesday, November 21, 2017, before the U.S. markets open. The Company will host a […]

iX Biopharma Starts Off 1Q18 on Sound Note

November 8, 2017

Singapore, 8 November 2017 – Specialty pharmaceutical company iX Biopharma Ltd (“iX Biopharma” or “the Group”) has reported results for its first financial quarter ended 30 September 2017 (“1Q18”) that reflects progress made in the development of its pharmaceutical products and preparations for the upcoming launch of its new range of next-generation nutraceutical products. Year-on-year, […]

Science Exchange Announces New Director of Scientific Content, Gursatya “Guru” Singh

November 8, 2017

PALO ALTO, Calif. — Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), announced today that Gursatya “Guru” Singh has joined the company’s management team as Director of Scientific Content. “Adding Guru to our team is part of our ongoing commitment to strengthen the management team with industry experts who are […]

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

November 8, 2017

PALO ALTO, Calif.– Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform as the primary marketplace to offer access to its predictive drug discovery assays for the biopharma research community. With REPROCELL as one of […]

BioIVT to Present Advances in Immunohistochemistry at AAPS Annual Meeting

November 8, 2017

BioIVT will also showcase its expanded research services resulting from its Qualyst Transporter Solutions and Asterand Bioscience™ acquisitions earlier this year BioIVT, a leading provider of biospecimens and related services, today announced that it will be presenting and exhibiting at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. This conference will be held from […]

Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates

November 8, 2017

CRANBURY, N.J., Nov. 08, 2017 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced financial results for the third quarter ended September 30, 2017. The Company also summarized recent program updates and reiterated full-year 2017 financial guidance. John F. Crowley, Chairman and […]

Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018

November 8, 2017

BOSTON, Nov. 08, 2017 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results and provided an update on financial, clinical and regulatory filing activities for the quarter ended September 30, 2017. “Following the successful completion of our […]

Protalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corporate Update

November 8, 2017

CARMIEL, Israel, Nov. 08, 2017 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the nine months ended September 30, 2017 and provided a corporate update. “I […]

Curis Reports Third Quarter 2017 Financial Results

November 7, 2017

LEXINGTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, reported today its financial results for the third quarter ended September 30, 2017. “We are pleased to announce the acceptance of our Investigational […]

Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results

November 7, 2017

BOSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) — Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial results for the quarter ended September 30, 2017. The company also reviewed its progress with Auryxia, upcoming milestones, and withdrew its 2017 financial guidance. “Auryxia prescriptions grew […]

Bioclinica Acquires MDDX Research & Informatics Combining Advanced Image Management Cloud Technology with Its Scientific and Medical Imaging Leadership

November 7, 2017

Best-in-class solution ensures sponsors and CROs have global access to efficient, accurate, and scalable medical imaging to drive better data and outcomes DOYLESTOWN, Pa., Nov. 6, 2017 – Bioclinica®, the world-leading provider of scientific-enabled Medical Imaging, eHealth, and patient-centric solutions supporting clinical research, today announces it has acquired Silicon Valley-based MDDX Research & Informatics, adding […]

Almirall, the leading manufacturer of skin medicine, opts for Werum’s PAS-X MES

November 7, 2017

Established implementation method and convincing process know-how as crucial factors / Rollout in German plant in Reinbek near Hamburg Lüneburg, Germany, November 7, 2017 – In the context of a tendering process, the Spanish pharmaceutical company Almirall opted for Werum’s PAS-X Manufacturing Execution System to be installed in the German plant in Reinbek near Hamburg. […]

Growing Biomedical Research Organization AMPEL BioSolutions Selects Montrium as eTMF Partner

November 7, 2017

Charlottesville, Virginia (November 7, 2017) — Today, Montrium announced that AMPEL BioSolutions has chosen Montrium’s eTMF Connect platform as their eTMF management solution. Finding an experienced technology partner was key for AMPEL BioSolutions as they are looking to scale research efforts and continue growth. With over a decade of providing best-in-class technology products & professional […]

Chesapeake IRB and Schulman IRB Merge to Establish Premier Independent Institutional Review Board for Research

November 7, 2017

Columbia, Md., and Cincinnati, Ohio, November 7, 2017 (Business Wire) – Chesapeake IRB and Schulman IRB, the research industry’s two most respected institutional review boards (IRBs), have combined to create Advarra, the premier provider of IRB, institutional biosafety committee (IBC) and research compliance services in North America. The new organization will leverage mutual strengths in […]

FEEDBACK